Aummune

Company Overview

Snapshot

Founded in July 2017 by Guy Neev and Marius Nacht, Aummune operates with 1-10 employees. The company secured its Seed funding round in January 2018, with aMoon Fund participating as a lead investor.

Business overview

Aummune is a clinical-stage company focused on developing individualized immunotherapy treatments for solid tumors. Its proprietary platform utilizes an efficacy-driven selection process to create patient-specific tri-functional oligonucleotide drugs designed to induce cancer cell death and activate both innate and adaptive immune responses. The company's lead program, AM003, is currently in Phase 1 clinical trials, targeting patients with locally advanced and metastatic solid tumors within the pharmaceuticals and life sciences sectors globally.

Company Intelligence Q&A

What is Aummune's primary focus?

Aummune is focused on developing individualized immunotherapy treatments for solid tumors, utilizing a proprietary platform to create patient-specific tri-functional oligonucleotide drugs.

When was Aummune founded and by whom?

Aummune was founded in July 2017 by Guy Neev and Marius Nacht.

What is the current status of Aummune's lead program?

Aummune's lead program, AM003, initiated its Phase 1 clinical trial following successful demonstrations of efficacy and safety in multiple animal models. The company is actively recruiting patients for this First-in-Human study.

Which investor participated in Aummune's Seed funding round?

Aummune secured Seed funding in January 2018, with aMoon Fund participating as a lead investor.

What markets does Aummune target?

Aummune targets the global market, specifically within the healthcare and life sciences industries, focusing on pharmaceuticals.